Inhibition of catechol-O-methyltransferase by 6,7-dihydroxy-3,4-dihydroisoquinolines related to dopamine: demonstration using liquid chromatography and a novel substrate for O-methylation.
We report that 6,7-dihydroxy-3,4-dihydroisoquinolines related to dopamine are potent inhibitors of catechol-O-methyltransferase (COMT), but are not apparent substrates for the enzyme in vitro or in vivo. Three dihydroxy (catecholic) dihydroisoquinolines, including the 1-benzyl (DesDHP) and the 1-methyl (DSAL) analogs, were found to inhibit COMT activity in rat liver supernatant more effectively than the well-known inhibitor, tropolone. Inhibition of O-methylation was uncompetitive with substrate, and O-methylated products of the catecholic dihydroisoquinolines were undetectable. For these in vitro studies, a facile liquid chromatographic assay was developed utilizing as a site-specific substrate, 1-methyl-6,7-dihydroxy-tetrahydroisoquinoline-1-carboxylate (salsolinol-1-carboxylate). This catechol produces only one phenolic product isomer when incubated with liver supernatant and S-adenosylmethionine. Following central injection of DSAL in rats, inhibition of brain COMT in vivo was indicated by the reduced brain levels of homovanillic acid, but not of 3,4-dihydroxyphenylacetic acid. Furthermore, O-methylated DSAL metabolites could not be detected in brain by liquid or gas chromatography. We suggest that 6,7-dihydroxy-dihydroisoquinolines are "nonmethylatable" COMT inhibitors because they exist as quinoidal tautomers resembling pyridones or tropolones rather than as catechols. Quinoid formation is supported by the fluorescence and ultraviolet spectra for DSAL and its O-methyl derivatives. The experiments reveal a new class of COMT inhibitors that may be of pharmacological and mechanistic value. Additionally, 3,4-dihydroisoquinolines could arise endogenously via oxidation of the 1,2,3,4-tetrahydroisoquinolines which are ingested or produced from cellular catecholamine condensations. However, it is unlikely that dihydroisoquinoline (e.g., DSAL) concentrations necessary to inhibit COMT significantly would be attained via endogenous pathways.
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000818:Animals; D065098:Catechol O-Methyltransferase Inhibitors; D002853:Chromatography, Liquid; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism; D004298:Dopamine / Q000031:analogs & derivatives*; D006719:Homovanillic Acid / Q000378:metabolism; D006863:Hydrogen-Ion Concentration; D006897:Hydroxyindoleacetic Acid / Q000378:metabolism; D006900:Hydroxylation; D007031:Hypothalamus / Q000187:drug effects / Q000378:metabolism; D007546:Isoquinolines / Q000378:metabolism / Q000494:pharmacology; D008099:Liver / Q000201:enzymology; D008297:Male; D008745:Methylation; D010208:Papaverine / Q000031:analogs & derivatives*; D051381:Rats; D011919:Rats, Inbred Strains; D013053:Spectrophotometry; D013765:Tetrahydropapaveroline / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology
D065098:Catechol O-Methyltransferase Inhibitors; D007546:Isoquinolines; D015102:3,4-Dihydroxyphenylacetic Acid; C051346:3',4'-desoxy-3,4-dihydropapaveroline; C051345:1,2-dehydrosalsolinol; D013765:Tetrahydropapaveroline; D006897:Hydroxyindoleacetic Acid; C048152:1-carboxysalsolinol; D010208:Papaverine; D004298:Dopamine; D006719:Homovanillic Acid